News

Under the terms of the agreement, current International Bio Immune Systems (IBS) shareholders will have the opportunity to become shareholders in Neogenix. Additional terms of the transaction have

Enrollment is now closed in this study to assess the safety and efficacy of Augment for the treatment of foot and ankle fusions as compared to autograft, the

According to BioSeek, under the collaboration, it will, over the next year, both carry out broad-based profiling of selected UCB new chemical and biological entities, and guide lead

Chiome and Chugai will develop novel value-added therapeutic monoclonal antibodies employing Chiome’s autonomously diversifying library (ADLib) system and will apply the system to assessment of target proteins and

The study, which is underway in Canada, has recruited 120 patients with confirmed cat allergies, and all the participants have completed screening and initial dosing with none experiencing

The acquired hematology business will continue to operate under the name Biocode Hycel, which has operations near Rennes, France. The business will be vertically integrated into Escalon’s clinical

Galapagos has also reached milestones on other compounds in the alliance, triggering payments totaling E7.6 million to Galapagos. To date, Galapagos has earned a total of E25.5 million

The depositary for the tender offer has advised GlaxoSmithKline (GSK) that shareholders of Genelabs have tendered and not withdrawn a total of approximately 39.25 million shares of Genelabs

ImQuest anticipates initiating its Phase I studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside